XNASCVKD
Market cap31mUSD
Jan 17, Last price
17.40USD
1D
-4.40%
1Q
0.81%
IPO
-70.41%
Name
Cadrenal Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-8m
L+24.47%
CFO
-4m
L+193.03%
Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2023‑12 | 2022‑12 | |
| Income | ||
Revenues | ||
Cost of revenue | 7,633 | 394 |
Unusual Expense (Income) | ||
NOPBT | (7,633) | (394) |
NOPBT Margin | ||
Operating Taxes | 4 | |
Tax Rate | ||
NOPAT | (7,633) | (394) |
Net income | (8,357) 24.47% | (6,714) |
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | 11,903 | 1,240 |
BB yield | -123.54% | |
| Debt | ||
Debt current | 43 | 66 |
Long-term debt | 21 | 618 |
Deferred revenue | ||
Other long-term liabilities | 4,420 | |
Net debt | (8,338) | 652 |
| Cash flow | ||
Cash from operating activities | (3,530) | (1,205) |
CAPEX | (3) | |
Cash from investing activities | (3) | (2) |
Cash from financing activities | 11,903 | 1,240 |
FCF | (8,152) | |
| Balance | ||
Cash | 8,402 | 33 |
Long term investments | ||
Excess cash | 8,402 | 33 |
Stockholders' equity | (15,058) | (6,706) |
Invested Capital | 22,793 | 6,216 |
ROIC | ||
ROCE | 80.39% | |
| EV | ||
Common stock shares outstanding | 868 | 776 |
Price | 11.10 | |
Market cap | 9,636 | |
EV | 1,297 | |
EBITDA | (7,631) | (393) |
EV/EBITDA | ||
Interest | 17 | 107 |
Interest/NOPBT | ||